KRAS MUTANT SOLID TUMORS

Clinical trials for KRAS MUTANT SOLID TUMORS explained in plain language.

Never miss a new study

Get alerted when new KRAS MUTANT SOLID TUMORS trials appear

Sign up with your email to follow new studies for KRAS MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug targets tough KRAS cancers in first human trial

Disease control Recruiting now

This early-stage trial is testing a new drug called TLN-372, both alone and combined with other cancer treatments, in people with advanced solid tumors driven by a specific KRAS gene mutation. The main goals are to find a safe dose, see how the drug moves through the body, and ch…

Matched conditions: KRAS MUTANT SOLID TUMORS

Phase: PHASE1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control

Last updated Mar 25, 2026 14:09 UTC

KRAS MUTANT SOLID TUMORS

Get alerted when new KRAS MUTANT SOLID TUMORS trials appear

New drug targets tough KRAS cancers in first human trial